Antidepressant Market in the US 2015-2019: Key Vendors are Actavis, Eli Lilly, GSK, Otsuka Pharmaceutical and Pfizer
Research and Markets has announced the addition of the "Antidepressant Market in the US 2015-2019" report to their offering.
Increased awareness of depression among the medical community, patients, and the families of patients is one major trend in this market. This can result in an increase in the number of treatment-seeking patients, which, in turn, can result in an increase in the overall consumption of medicines.
According to the report, an increase in patient population and changes in lifestyles are major factors propelling the growth of the market. Current treatment options do not provide a cure for the disorder, hence, there is a significant unmet need in the market. Therefore, drugs that can cause remission of depression in patients are expected to drive the growth of the market.
Further, the report states that one of the major challenges in the market is the expiry of the patents of major branded drugs, which is expected to lead to the erosion of their market share and a fall in the revenue generated by them. This is also expected to impact the size of the Antidepressant market in the US.
The study was conducted using an objective combination of primary and secondary information, including inputs from key participants in the industry.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
06. Introduction
07. Disorder Overview
08. Market Landscape
09. Market Segmentation by Mechanism of Action
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
18. Key Vendor Analysis
19. Other Reports in this Series
Companies Mentioned:
Abbott Laboratories
Actavis
AstraZeneca
Aurobindo Pharma
Bristol-Myers Squibb
Dr. Reddy's Laboratories
Eli Lilly and Company
GlaxoSmithKline
H. Lundbeck
Janssen Pharmaceuticals
Lupin
Novartis
Otsuka Pharmaceutical
Pfizer
Pierre Fabre
Shire
Somerset Pharmaceuticals
Sun Pharmaceutical
Sunovion Pharmaceuticals
Takeda Pharmaceutical
Teva Pharmaceutical
Torrent Pharmaceuticals
Valeant Pharmaceuticals
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance